Thus, receptor specific interventions activating the Y1R/Y5R pathway, inhibiting Y2R/Y5Rs, and/or targeting DPPIV may provide new therapeutic opportunities for ES patients. The gene discussed is DPP4; the disease is Ewing sarcoma.